Biopharmaceutical Process Analytical Technology Market

Biopharmaceutical Process Analytical Technology Market Size by Technology (LC, GC, MS, qPCR, NGS, NMR, Raman, IR Spectroscopy), Product (Analyzer, Sensor, Software), Application (Vaccine, Biologics, CGT), and End User - Global Forecast to 2029

Report Code: AST 9019 May, 2024, by marketsandmarkets.com

The size of global biopharmaceutical process analytical technology market in terms of revenue was estimated to be worth $1.2 billion in 2024 and is poised to reach $2.6 billion by 2029, growing at a CAGR of 16.0% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The market is witnessing a surge in growth propelled by rising investments, both direct and indirect, in analytical instruments, coupled with strategic partnerships aimed at advancing drug discovery. Furthermore, the global biosimilar sector is on an upward trajectory, driven by these factors alongside the increasing number of conferences and symposia dedicated to analytical technologies. Looking forward, emerging markets are expected to offer promising opportunities for industry players in the coming five years.

Biopharmaceutical Process Analytical Technology Market

Biopharmaceutical Process Analytical  Technology Market

To know about the assumptions considered for the study, Request for Free Sample Report

Biopharmaceutical Process Analytical  Technology Market

e- Estimated; p- Projected

Biopharmaceutical Process Analytical Technology Market: Market Dynamics

Driver: Increasing demand for enhancing the quality of manufacturing processes

PAT instruments are sturdy instruments utilized for analyzing and managing Critical Quality Attributes (CQAs) within biopharmaceutical manufacturing workflows by assessing Critical Process Parameters (CPPs). These instruments play a pivotal role in enhancing production efficiency, ensuring top-notch product quality, and enhancing overall product performance. Through PAT, continuous monitoring of biopharmaceutical manufacturing is enabled, furnishing real-time insights into product quality and mitigating the need for batch reprocessing or disposal. This technology not only facilitates cost control but also accelerates product release by circumventing post-production testing, thereby offering financial advantages. Moreover, it diminishes cycle times and energy consumption associated with equipment operation. Automation within the process further trims labor expenses, contributing to overall cost savings.

Restraint: High cost of PAT deployment

Technological advancements have led to an escalation in the prices of various systems. For example, the price range for a new spectroscopy instrument is between USD 75,000 and USD 500,000. An HPLC system can cost anywhere from USD 10,000 to USD 40,000, while a dynamic light-scattering particle size analyzer may be priced in the range of USD 30,000 to USD 60,000, depending on accompanying accessories. Despite the operational advantages and potential cost savings associated with implementing Process Analytical Technology (PAT) in the biopharmaceutical sector, its uptake has been sluggish in emerging markets.

Opportunity: Healthcare costs are on the rise in developing nations

Emerging markets across Asia, including China, South Korea, Indonesia, and India, are poised to offer significant growth prospects for Process Analytical Technology (PAT). This is primarily driven by more lenient regulatory frameworks, a rising number of biopharmaceutical firms, a skilled workforce, and governmental efforts to bolster local manufacturing. Specifically, China and India represent key opportunities for PAT market expansion. These nations exhibit substantial demand for devices like spectrometers and chromatography instruments, driven by the establishment of new projects across various industries. Moreover, the robust biopharmaceutical sectors in China and India are expected to notably contribute to the growth of spectroscopy and chromatography markets in the foreseeable future.

Challenge: Lack of skilled professionals

The biopharmaceutical industry faces challenges due to a lack of skilled professionals in the field of process analytical technology (PAT). PAT involves the use of advanced analytical tools and techniques to monitor and control biopharmaceutical manufacturing processes in real time. The shortage of skilled professionals in PAT can hinder the implementation and optimization of these technologies, leading to inefficiencies in manufacturing processes, increased costs, and potential delays in bringing new therapies to market. Addressing this shortage requires investment in education and training programs to develop the necessary expertise in PAT among scientists, engineers, and technicians within the biopharmaceutical industry.

Biopharmaceutical Process Analytical Technology Industry Ecosystem/Map

Biopharmaceutical Process Analytical  Technology Market Ecosystem

By type, the mass spectrometry segment of the biopharmaceutical process analytical technology industry accounted for the largest share in 2024.

Based on type, the biopharmaceutical process analytical technology market is segmented into liquid chromatography/HPLC, GAS chromatography, mass spectrometry, real-time PCR/QPCR, NGS, NMR spectroscopy, raman spectroscopy, infrared spectroscopy, particle counters and imaging, differential light scattering, and other techniques. In 2024, the liquid chromatography/HPLC segment accounted for the largest market share. Liquid chromatography is essential for gathering quantitative data in drug development, particularly regarding pharmacokinetics and pharmacodynamics, in conjunction with chromatography. Its widespread use in both qualitative and quantitative analyses of pharmaceutical and biopharmaceutical products is anticipated to drive substantial growth in the spectroscopy sector in the foreseeable future.

By product type, the analyzers segment of the biopharmaceutical process analytical technology industry accounted for the largest share during the forecast period.

Biopharmaceutical process analytical products include analyzers, sensors & probes, samplers, and software. In 2023, the analyzer segment accounted for the largest share of the biopharmaceutical process analytical technology market. The need for analyzers in pharmaceutical production is mainly driven by the necessity for smoother and more effective manufacturing procedures, strict regulations guaranteeing product quality and performance, and the increasing amount of research and development initiatives within the biopharmaceutical industry.

By application, the medical application market will register significant growth of the biopharmaceutical process analytical technology industry in the near future.

Based on application, the biopharmaceutical process analytical technology market is broadly segmented into vaccines, cell and gene therapy, biosimilars & biologics, hormonal therapy, and other applications. The biosimilars & biologics segment to register the highest growth from 2024 to 2029. In recent times, research has become pivotal in the advancement of pharmaceuticals, offering pathways for addressing a multitude of medical ailments such as cancer, rheumatoid arthritis, psoriasis, Crohn's disease, and diabetes, among various others. As a result, the growing incidence of chronic illnesses, coupled with heightened research endeavors aimed at vaccine development, is driving the growth of this industry.

By region, North America is expected to be the largest market of the biopharmaceutical process analytical technology industry during the forecast period .

North America, comprising the US and Canada, accounted for the largest share of the biopharmaceutical process analytical technology market in 2023. The significant growth of the North American market can largely be attributed to the strict FDA regulations overseeing drug approval and safety, the strong presence of pharmaceutical companies, and the swift adoption of cutting-edge technologies. Other factors contributing to the market's expansion in North America include increased investment in biotechnology research and a growing demand for biologics.

Biopharmaceutical Process Analytical  Technology Market by Region

To know about the assumptions considered for the study, download the pdf brochure

As of 2023, the key players operating in the global process analytical technology market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Shimadzu Corporation (Japan), Waters Corporation (US), Bruker Corporation (US), Emerson Electric Co. (US), ABB Ltd. (Switzerland), PerkinElmer, Inc. (US), Mettler-Toledo International Inc. (US), and Carl Zeiss AG (Germany), among others.

Scope of the Biopharmaceutical Process Analytical Technology Industry:

Report Metric

Details

Market Revenue in 2024

$1.2 billion

Projected Revenue by 2029

$2.6 billion

Revenue Rate

Poised to Grow at a CAGR of 16.0%

Market Driver

Increasing demand for enhancing the quality of manufacturing processes

Market Opportunity

Healthcare costs are on the rise in developing nations

This report has segmented the biopharmaceutical process analytical technology market to forecast revenue and analyze trends in each of the following submarkets:

By Type
  • Liquid Chromatography/HPLC
  • GAS Chromatography (GC)
  • Mass Spectrometry
  • Real-Time PCR/QPCR
  • NGS
  • NMR Spectroscopy
  • Raman Spectroscopy
  • Infrared Spectroscopy
  • Particle Counters and Imaging
  • Differential Light Scattering
  • Other Techniques
By Product Type
  • Analyzers
  • Sensor and Probes
  • Samples
  • Software
By Mode
  • On-line Measurement
  • Off-line Measurement
  • At-line Measurement
  • In-line Measurement
By Application
  • Vaccines
  • Cell and Gene Therapy
  • Biosimilars & Biologics
  • Hormonal Therapy
  • Other Application
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
  • GCC Countries

Recent Developments of the Biopharmaceutical Process Analytical Technology Industry:

  • In Feb 2024, Thermo Fisher Scientific Inc. introduced the Thermo Scientific Dionex Inuvion Ion Chromatography (IC) system, aimed at simplifying, and enhancing ion analysis across laboratories of varying scales. This innovative analytical instrument offers easy reconfiguration, serving as a comprehensive solution for the precise determination of ionic and small polar compounds, ensuring consistent and reliable results.
  • In April 2022, Thermo Fisher Scientific Inc. has introduced the Ramina Process Analyzer, a Raman spectroscopic analyzer aimed at simplifying Raman spectroscopy measurements to enhance user accessibility by reducing complexity.
  • In June 2021, Agilent Technologies Inc. launched three InfinityLab Bio LC systems have been introduced by the company, tailored to address the increasing demands of the biopharmaceutical sector.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 30)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED
           1.3.3 CURRENCY CONSIDERED
    1.4 RESEARCH LIMITATIONS 
    1.5 STAKEHOLDERS 
    1.6 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Primary sources
                    2.1.2.2 Key industry insights
                    2.1.2.3 Breakdown of primaries
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 BOTTOM-UP APPROACH
                    2.2.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 5 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
                    2.2.1.2 Approach 2: Customer-based market estimation
                                FIGURE 6 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY SIZE ESTIMATION: BOTTOM-UP APPROACH
                    2.2.1.3 Growth forecast
                    2.2.1.4 CAGR projection
                                FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
    2.3 DATA VALIDATION APPROACH 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ASSESSMENT 
    2.5 STUDY ASSUMPTIONS 
    2.6 GROWTH RATE ASSUMPTIONS 
    2.7 RESEARCH LIMITATIONS 
    2.8 RISK ASSESSMENT 
    2.9 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 11 MARKET, BY APPLICATION, 2024 VS. 2029
    FIGURE 12 MARKET: GEOGRAPHICAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET OVERVIEW 
          FIGURE 13 GROWING R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH
    4.2 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY, BY MODE 
          FIGURE 14 ONLINE MEASUREMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.3 MARKET, BY REGION AND APPLICATION 
          FIGURE 15 NORTH AMERICA TO HOLD LARGEST SHARE OF ALL APPLICATION SEGMENTS IN 2024
    4.4 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising R&D investments by pharma companies and governments in emerging markets
                                FIGURE 18 PHARMACEUTICAL R&D EXPENDITURE: ANNUAL GROWTH RATE (%)
                    5.2.1.2 Growing incidence of infectious diseases and essential contribution of PAT in vaccine development
                    5.2.1.3 Requirement for improved efficiency in manufacturing processes driving enhancements in quality
                    5.2.1.4 Advancements in analytical device technology
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of process analytical technology deployment
                    5.2.2.2 Governmental regulations pertaining to safety of drugs
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing interest in PAT in emerging markets
                    5.2.3.2 Increasing utilization of analytical instruments in biopharmaceutical processes
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of skilled professionals
    5.3 REGULATORY ANALYSIS 
           5.3.1 REGULATORY LANDSCAPE
                    TABLE 1 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PROCESS ANALYTICAL TECHNOLOGY, BY COUNTRY/REGION
           5.3.2 KEY REGULATORY BODIES & GOVERNMENT AGENCIES
                    TABLE 2 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 3 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 4 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 5 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.3.3 KEY REGULATORY GUIDELINES
                    5.3.3.1 US
                    5.3.3.2 Europe
                    5.3.3.3 Asia Pacific
                    5.3.3.4 Rest of the World
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 19 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY: VALUE CHAIN ANALYSIS
    5.5 SUPPLY CHAIN ANALYSIS 
           5.5.1 PROMINENT COMPANIES
           5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
           5.5.3 END USERS
                    FIGURE 20 MARKET: SUPPLY CHAIN ANALYSIS
    5.6 ECOSYSTEM ANALYSIS 
          FIGURE 21 MARKET: ECOSYSTEM ANALYSIS
          TABLE 7 MARKET: ROLE IN ECOSYSTEM
    5.7 INVESTMENT & FUNDING SCENARIO 
          FIGURE 22 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022
          FIGURE 23 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 (USD MILLION)
    5.8 PRICING ANALYSIS 
          FIGURE 24 AVERAGE SELLING PRICE TREND OF MAJOR PROCESS ANALYTICAL TECHNOLOGIES, BY TYPE (USD THOUSAND)
          FIGURE 25 AVERAGE SELLING PRICE TREND OF MAJOR PROCESS ANALYTICAL TECHNOLOGIES, BY REGION (USD THOUSAND)
          TABLE 8 AVERAGE SELLING PRICE OF PROCESS ANALYTICAL TECHNOLOGIES,  BY REGION, 2021–2023 (USD THOUSAND)
    5.9 TRADE ANALYSIS 
           5.9.1 IMPORT DATA
                    TABLE 9 IMPORT DATA FOR CHROMATOGRAPHY SYSTEMS (HS CODE 902720), BY COUNTRY, 2019–2023 (USD THOUSAND)
                    TABLE 10 IMPORT DATA FOR SPECTROMETERS, SPECTROPHOTOMETERS, AND SPECTROGRAPHS (HS CODE 902730), BY COUNTRY, 2019–2023 (USD THOUSAND)
           5.9.2 EXPORT DATA
                    TABLE 11 EXPORT DATA FOR CHROMATOGRAPHY SYSTEMS (HS CODE 902720), BY COUNTRY, 2019–2023 (USD THOUSAND)
                    TABLE 12 EXPORT DATA FOR SPECTROMETERS, SPECTROPHOTOMETERS, AND SPECTROGRAPHS (HS CODE 902730), BY COUNTRY, 2019–2023 (USD THOUSAND)
    5.10 PATENT ANALYSIS 
           5.10.1 PATENT DETAILS FOR BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (JANUARY 2013–DECEMBER 2023)
    5.11 PORTER’S FIVE FORCE ANALYSIS 
           TABLE 13 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF SUPPLIERS
           5.11.4 BARGAINING POWER OF BUYERS
           5.11.5 INTENSITY OF COMPETITIVE RIVALRY
    5.12 KEY CONFERENCES & EVENTS 
           TABLE 14 LIST OF MAJOR CONFERENCES & EVENTS IN MARKET IN JANUARY 2024-DECEMBER 2024
    5.13 CASE STUDY ANALYSIS 
           5.13.1 NAVIGATING DIGITAL TRANSFORMATION: INTEGRATING ADVANCED TECHNOLOGIES FOR PAT IN BIOPHARMACEUTICAL MANUFACTURING.
                    5.13.1.1 Case 1: Advancements in process analytical technology
    5.14 TECHNOLOGY ANALYSIS 
           5.14.1 KEY TECHNOLOGIES
                    5.14.1.1 Mass spectrometry (MS)
                    5.14.1.2 Liquid chromatography/HPLC
           5.14.2 COMPLEMENTARY TECHNOLOGIES
                    5.14.2.1 Advanced sensor technologies
           5.14.3 ADJACENT TECHNOLOGIES
                    5.14.3.1 Bioprocess monitoring and control systems
    5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 26 REVENUE SHIFT IN MARKET
    5.16 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES
                     TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
           5.16.2 BUYING CRITERIA
                     FIGURE 28 KEY BUYING CRITERIA FOR PROCESS ANALYTICAL TECHNOLOGY
                     TABLE 16 KEY BUYING CRITERIA FOR PROCESS ANALYTICAL TECHNOLOGY
    5.17 UNMET NEEDS AND KEY PAIN POINTS 
           TABLE 17 MARKET: CURRENT UNMET NEEDS
 
6 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE (Page No. - )
    6.1 INTRODUCTION 
          TABLE 18 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 19 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY VOLUME, BY TYPE, 2022–2029 (MILLION UNITS)
          TABLE 20 MARKET, BY REGION,  2022–2029 (USD MILLION)
    6.2 LIQUID CHROMATOGRAPHY/HPLC 
           6.2.1 EARLY AND EFFICIENT SAMPLE ANALYSIS ASSOCIATED WITH LC TO DRIVE MARKET GROWTH
                    TABLE 21 DIFFERENTIATION OF LIQUID CHROMATOGRAPHY SYSTEMS
                    TABLE 22 MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 23 MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY MODE, 2022–2029 (USD MILLION)
                    TABLE 24 MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY APPLICATION, 2022–2029 (USD MILLION)
    6.3 GAS CHROMATOGRAPHY 
           6.3.1 GROWING ADOPTION OF COMPACT GC SYSTEMS IN MANUFACTURING FACILITIES TO BOLSTER GROWTH
                    TABLE 25 MARKET FOR GAS CHROMATOGRAPHY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 26 MARKET FOR GAS CHROMATOGRAPHY, BY MODE, 2022–2029 (USD MILLION)
                    TABLE 27 MARKET FOR GAS CHROMATOGRAPHY, BY APPLICATION, 2022–2029 (USD MILLION)
    6.4 MASS SPECTROMETRY 
           6.4.1 GROWING NEED FOR DUAL-MASS ANALYZERS TO PROPEL GROWTH
                    TABLE 28 MARKET FOR MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 29 MARKET FOR MASS SPECTROMETRY, BY MODE, 2022–2029 (USD MILLION)
                    TABLE 30 MARKET FOR MASS SPECTROMETRY, BY APPLICATION, 2022–2029 (USD MILLION)
    6.5 REAL-TIME PCR/QPCR 
           6.5.1 EXPANSION OF PCR INSTRUMENTATION TO FAVOR MARKET GROWTH
                    TABLE 31 MARKET FOR REAL-TIME PCR/QPCR, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 32 MARKET FOR REAL-TIME PCR/QPCR, BY MODE, 2022–2029 (USD MILLION)
                    TABLE 33 MARKET FOR REAL-TIME PCR/QPCR, BY APPLICATION, 2022–2029 (USD MILLION)
    6.6 NEXT-GENERATION SEQUENCING 
           6.6.1 INCREASING INVESTMENTS IN NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGIES TO DRIVE MARKET EXPANSION
                    TABLE 34 MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 35 MARKET FOR NEXT-GENERATION SEQUENCING, BY MODE, 2022–2029 (USD MILLION)
                    TABLE 36 MARKET FOR NEXT-GENERATION SEQUENCING, BY APPLICATION, 2022–2029 (USD MILLION)
    6.7 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
           6.7.1 ADVANCING BIOPHARMACEUTICAL QUALITY AND EFFICIENCY THROUGH NMR SPECTROSCOPY TO BOOST MARKET
                    TABLE 37 MARKET FOR NMR SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 38 MARKET FOR NMR SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION)
                    TABLE 39 MARKET FOR NMR SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION)
    6.8 RAMAN SPECTROSCOPY 
           6.8.1 EXPANDING ROLE OF RAMAN SPECTROSCOPY IN PROCESS MONITORING AND QUALITY CONTROL TO BOOST MARKET
                    TABLE 40 MARKET FOR RAMAN SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 41 MARKET FOR RAMAN SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION)
                    TABLE 42 MARKET FOR RAMAN SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION)
    6.9 INFRARED SPECTROSCOPY 
           6.9.1 INCREASING UTILIZATION OF MINIATURIZED GC SYSTEMS IN PRODUCTION PLANTS TO SUPPORT GROWTH
                    TABLE 43 MARKET FOR INFRARED SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 44 MARKET FOR INFRARED SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION)
                    TABLE 45 MARKET FOR INFRARED SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION)
    6.10 PARTICLE COUNTERS & IMAGING 
           6.10.1 INCREASING DEMAND FOR HIGH-QUALITY MEDICATIONS WITH REDUCED SIDE EFFECTS TO FACILITATE MARKET ACCEPTANCE
                     TABLE 46 MARKET FOR PARTICLE COUNTERS & IMAGING, BY REGION, 2022–2029 (USD MILLION)
                     TABLE 47 MARKET FOR PARTICLE COUNTERS & IMAGING, BY MODE, 2022–2029 (USD MILLION)
                     TABLE 48 MARKET FOR PARTICLE COUNTERS & IMAGING, BY APPLICATION, 2022–2029 (USD MILLION)
    6.11 DIFFERENTIAL LIGHT SCATTERING 
           6.11.1 CONTROLLED MANUFACTURING OF PHARMACEUTICALS WITH FEWER SIDE EFFECTS TO BOOST ADOPTION
                     TABLE 49 MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY REGION, 2022–2029 (USD MILLION)
                     TABLE 50 MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY MODE, 2022–2029 (USD MILLION)
                     TABLE 51 MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY APPLICATION, 2022–2029 (USD MILLION)
    6.12 OTHER TECHNIQUES 
           TABLE 52 MARKET FOR OTHER TECHNIQUES, BY REGION, 2022–2029 (USD MILLION)
           TABLE 53 MARKET FOR OTHER TECHNIQUES, BY MODE, 2022–2029 (USD MILLION)
           TABLE 54 MARKET FOR OTHER TECHNIQUES, BY APPLICATION, 2022–2029 (USD MILLION)
 
7 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE (Page No. - 109)
    7.1 INTRODUCTION 
          TABLE 55 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
    7.2 ANALYZERS 
           7.2.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH
                    TABLE 56 MARKET FOR ANALYZERS,  BY REGION, 2022–2029 (USD MILLION)
    7.3 SENSORS & PROBES 
           7.3.1 QUICK TURNAROUND TIMES AND AUTOMATED PROCESSES TO FACILITATE MARKET ADOPTION
                    TABLE 57 MARKET FOR SENSORS & PROBES, BY REGION, 2022–2029 (USD MILLION)
    7.4 SAMPLERS 
           7.4.1 HIGH LEVEL OF ACCURACY AND REPRODUCIBILITY TO DRIVE MARKET GROWTH
                    TABLE 58 MARKET FOR SAMPLERS,  BY REGION, 2022–2029 (USD MILLION)
    7.5 SOFTWARE 
           7.5.1 GROWING ADOPTION OF PAT FRAMEWORKS WITHIN PHARMACEUTICAL COMPANIES TO BOLSTER ADOPTION
                    TABLE 59 MARKET FOR SOFTWARE,  BY REGION, 2022–2029 (USD MILLION)
 
8 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE (Page No. - 116)
    8.1 INTRODUCTION 
          TABLE 60 COMPARISON BETWEEN MEASUREMENT METHODS IN PAT
          TABLE 61 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY, BY MODE,  2022–2029 (USD MILLION)
    8.2 ONLINE MEASUREMENT 
           8.2.1 IMPROVED PROCESS EFFICIENCY AND REDUCED PRODUCTION COSTS TO BOOST ADOPTION
                    TABLE 62 MARKET FOR ONLINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
    8.3 OFFLINE MEASUREMENT 
           8.3.1 HIGH FLEXIBILITY OF OFFLINE ANALYSIS TO DRIVE GROWTH
                    TABLE 63 MARKET FOR OFFLINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
    8.4 AT-LINE MEASUREMENT 
           8.4.1 GROWING USE OF AT-LINE MEASUREMENT TO BOOST MARKET GROWTH
                    TABLE 64 MARKET FOR AT-LINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
    8.5 IN-LINE MEASUREMENT 
           8.5.1 FAST TURNAROUND TIME TO BOOST SEGMENTAL GROWTH
                    TABLE 65 MARKET FOR IN-LINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
 
9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,  BY APPLICATION (Page No. - 122)
    9.1 INTRODUCTION 
          TABLE 66 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
    9.2 VACCINES 
           9.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH FOR VACCINES
                    TABLE 67 MARKET FOR VACCINES,  BY REGION, 2022–2029 (USD MILLION)
    9.3 CELL & GENE THERAPY 
           9.3.1 GROWING DEMAND FOR STEM CELL AND CAR-T THERAPIES TO BOOST MARKET GROWTH
                    TABLE 68 MARKET FOR CELL & GENE THERAPY, BY REGION, 2022–2029 (USD MILLION)
    9.4 BIOSIMILARS & BIOLOGICS 
           9.4.1 HIGH LEVELS OF ACCURACY AND REPRODUCIBILITY TO PROPEL DEMAND FOR BIOSIMILARS & BIOLOGICS
                    TABLE 69 MARKET FOR BIOSIMILARS & BIOLOGICS, BY REGION, 2022–2029 (USD MILLION)
    9.5 HORMONAL THERAPY 
           9.5.1 IMPROVING CANCER TREATMENT WITH ADVANCED HORMONAL THERAPY TO FAVOR MARKET GROWTH
                    FIGURE 29 GLOBAL CANCER CASES, 202O VS. 2022
                    TABLE 70 MARKET FOR HORMONAL THERAPY, BY REGION, 2022–2029 (USD MILLION)
    9.6 OTHER APPLICATIONS 
          TABLE 71 MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
 
10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION (Page No. - 130)
     10.1 INTRODUCTION 
             TABLE 72 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY, BY REGION,  2022–2029 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 30 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT
             10.2.1 NORTH AMERICA: RECESSION IMPACT
                        TABLE 73 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 74 NORTH AMERICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 75 NORTH AMERICA: MARKET, BY MODE, 2022–2029 (USD MILLION)
                        TABLE 76 NORTH AMERICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
                        TABLE 77 NORTH AMERICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
             10.2.2 US
                        10.2.2.1 Stringent regulations and dominance of pharma and biopharma firms to propel market growth
                                      TABLE 78 US: MARKET, BY TYPE, 2022–2029 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Widespread occurrence of cancer and promising funding landscape to bolster market growth
                                      TABLE 79 CANADA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPE: RECESSION IMPACT
                        TABLE 80 EUROPE: MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 81 EUROPE: MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 82 EUROPE: MARKET, BY MODE, 2022–2029 (USD MILLION)
                        TABLE 83 EUROPE: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE,  2022–2029 (USD MILLION)
                        TABLE 84 EUROPE: MARKET,  BY APPLICATION, 2022–2029 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Growing adoption of biopharmaceutical process analytical technology (PAT) to propel market
                                      TABLE 85 GERMANY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Infrastructure development and increasing life science R&D investment to propel growth
                                      TABLE 86 FRANCE: MARKET, BY TYPE, 2022–2029 (USD MILLION)
             10.3.4 UK
                        10.3.4.1 Government initiatives to boost market expansion
                                      TABLE 87 UK: MARKET, BY TYPE,  2022–2029 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Conducive funding environment in Italy to boost market
                                      TABLE 88 ITALY: MARKET, BY TYPE, 2022–2029 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Growing focus on cancer screening and digital health initiatives to boost market
                                      TABLE 89 SPAIN: MARKET, BY TYPE, 2022–2029 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 90 REST OF EUROPE: MARKET, BY TYPE, 2022–2029 (USD MILLION)
     10.4 ASIA PACIFIC 
            FIGURE 31 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
                        TABLE 91 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 92 ASIA PACIFIC: MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 93 ASIA PACIFIC: MARKET, BY MODE, 2022–2029 (USD MILLION)
                        TABLE 94 ASIA PACIFIC: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE,  2022–2029 (USD MILLION)
                        TABLE 95 ASIA PACIFIC: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Advanced infrastructure to support market growth in Japan
                                      TABLE 96 JAPAN: MARKET, BY TYPE, 2022–2029 (USD MILLION)
             10.4.3 CHINA
                        10.4.3.1 Growing demand for PAT to boost market
                                      TABLE 97 CHINA: MARKET,  BY TYPE, 2022–2029 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Growing biopharmaceutical industry to drive market growth
                                      TABLE 98 INDIA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
             10.4.5 AUSTRALIA
                        10.4.5.1 Government investments to propel market growth
                                      TABLE 99 AUSTRALIA: MARKET,  BY TYPE, 2022–2029 (USD MILLION)
             10.4.6 SOUTH KOREA
                        10.4.6.1 Extensive insurance coverage to boost market growth
                                      TABLE 100 SOUTH KOREA: MARKET,  BY TYPE, 2022–2029 (USD MILLION)
             10.4.7 REST OF ASIA PACIFIC
                        TABLE 101 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 102 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                        TABLE 103 LATIN AMERICA: MARKET,  BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 104 LATIN AMERICA: MARKET,  BY MODE, 2022–2029 (USD MILLION)
                        TABLE 105 LATIN AMERICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
                        TABLE 106 LATIN AMERICA: MARKET,  BY APPLICATION, 2022–2029 (USD MILLION)
             10.5.2 BRAZIL
                        10.5.2.1 Expansion within biopharmaceutical sector to contribute to market growth
                                      TABLE 107 BRAZIL: MARKET, BY TYPE, 2022–2029 (USD MILLION)
             10.5.3 MEXICO
                        10.5.3.1 Growing exports of biopharmaceuticals to drive market in Mexico
                                      TABLE 108 MEXICO: MARKET, BY TYPE, 2022–2029 (USD MILLION)
             10.5.4 REST OF LATIN AMERICA
                        TABLE 109 REST OF LATIN AMERICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 110 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
                        TABLE 111 MIDDLE EAST & AFRICA: MARKET, BY MODE, 2022–2029 (USD MILLION)
                        TABLE 112 MIDDLE EAST & AFRICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
                        TABLE 113 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 169)
     11.1 OVERVIEW 
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET
                        TABLE 114 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURING COMPANIES
     11.3 REVENUE ANALYSIS 
             FIGURE 32 REVENUE ANALYSIS OF TOP THREE PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY (2019–2023)
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
             TABLE 115 MARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
             11.5.5 COMPANY FOOTPRINT: KEY PLAYERS
                        FIGURE 35 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY: COMPANY FOOTPRINT
                        TABLE 116 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY: PRODUCT FOOTPRINT
                        TABLE 117 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY: REGIONAL FOOTPRINT
     11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 RESPONSIVE COMPANIES
             11.6.3 DYNAMIC COMPANIES
             11.6.4 STARTING BLOCKS
                        FIGURE 36 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
             11.6.5 COMPETITIVE BENCHMARKING
                        TABLE 118 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
                        TABLE 119 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY INDUSTRY: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
     11.7 COMPANY VALUATION & FINANCIAL METRICS 
             FIGURE 37 EV/EBITDA OF KEY VENDORS
             FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF  KEY VENDORS
     11.8 BRAND/PRODUCT COMPARISON 
             FIGURE 39 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL
     11.9 COMPETITIVE SCENARIO 
             11.9.1 PRODUCT LAUNCHES
                        TABLE 120 MARKET: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
             11.9.2 DEALS
                        TABLE 121 MARKET: DEALS, JANUARY 2020–MARCH 2024
             11.9.3 EXPANSIONS
                        TABLE 122 MARKET: EXPANSIONS, JANUARY 2020–APRIL 2024
 
12 COMPANY PROFILES (Page No. - 191)
     12.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 WATERS CORPORATION
                        TABLE 123 WATERS CORPORATION: COMPANY OVERVIEW
                        FIGURE 40 WATERS CORPORATION: COMPANY SNAPSHOT (2023)
                        TABLE 124 WATERS CORPORATION: PRODUCTS OFFERED
                        TABLE 125 WATERS CORPORATION: DEALS
             12.1.2 DANAHER CORPORATION
                        TABLE 126 DANAHER CORPORATION: COMPANY OVERVIEW
                        FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
                        TABLE 127 DANAHER CORPORATION: PRODUCTS OFFERED
                        TABLE 128 DANAHER CORPORATION: DEALS
             12.1.3 THERMO FISHER SCIENTIFIC INC.
                        TABLE 129 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
                        TABLE 130 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
                        TABLE 131 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES
                        TABLE 132 THERMO FISHER SCIENTIFIC INC.: DEALS
             12.1.4 AGILENT TECHNOLOGIES, INC.
                        TABLE 133 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
                        FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
                        TABLE 134 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
                        TABLE 135 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES
                        TABLE 136 AGILENT TECHNOLOGIES, INC.: DEALS
             12.1.5 SHIMADZU CORPORATION
                        TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW
                        FIGURE 44 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2022)
                        TABLE 138 SHIMADZU CORPORATION: PRODUCTS OFFERED
                        TABLE 139 SHIMADZU CORPORATION: PRODUCT LAUNCHES
                        TABLE 140 SHIMADZU CORPORATION: EXPANSIONS
             12.1.6 PERKINELMER, INC.
                        TABLE 141 PERKINELMER, INC.: COMPANY OVERVIEW
                        FIGURE 45 PERKINELMER, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 142 PERKINELMER, INC.: PRODUCTS OFFERED
                        TABLE 143 PERKINELMER, INC.: PRODUCT LAUNCHES
             12.1.7 BRUKER CORPORATION
                        TABLE 144 BRUKER CORPORATION: COMPANY OVERVIEW
                        FIGURE 46 BRUKER CORPORATION: COMPANY SNAPSHOT (2023)
                        TABLE 145 BRUKER CORPORATION: PRODUCTS OFFERED
                        TABLE 146 BRUKER CORPORATION: PRODUCT LAUNCHES
                        TABLE 147 BRUKER CORPORATION: DEALS
             12.1.8 METTLER-TOLEDO INTERNATIONAL INC.
                        TABLE 148 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY OVERVIEW
                        FIGURE 47 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY SNAPSHOT (2023)
                        TABLE 149 METTLER-TOLEDO INTERNATIONAL INC.: PRODUCTS OFFERED
                        TABLE 150 METTLER-TOLEDO INTERNATIONAL INC.: DEALS
             12.1.9 CARL ZEISS AG (ZEISS GROUP)
                        TABLE 151 CARL ZEISS AG: COMPANY OVERVIEW
                        FIGURE 48 CARL ZEISS AG: COMPANY SNAPSHOT (2022)
                        TABLE 152 CARL ZEISS AG: PRODUCTS OFFERED
             12.1.10 EMERSON ELECTRIC CO.
                        TABLE 153 EMERSON ELECTRIC CO.: COMPANY OVERVIEW
                        FIGURE 49 EMERSON ELECTRIC CO.: COMPANY OVERVIEW
                        TABLE 154 EMERSON ELECTRIC CO.: PRODUCTS OFFERED
             12.1.11 ABB
                        TABLE 155 ABB: COMPANY OVERVIEW
                        FIGURE 50 ABB: COMPANY SNAPSHOT (2023)
                        TABLE 156 ABB: PRODUCTS OFFERED
                        TABLE 157 ABB: EXPANSIONS
             12.1.12 SARTORIUS AG
                        TABLE 158 SARTORIUS AG: COMPANY OVERVIEW
                        FIGURE 51 SARTORIUS AG: COMPANY SNAPSHOT (2023)
                        TABLE 159 SARTORIUS AG: PRODUCTS OFFERED
                        TABLE 160 SARTORIUS AG: DEALS
                        TABLE 161 SARTORIUS AG: EXPANSIONS
             12.1.13 PROCESS INSIGHTS, INC.
                        TABLE 162 PROCESS INSIGHTS, INC.: COMPANY OVERVIEW
                        TABLE 163 PROCESS INSIGHTS, INC.: PRODUCTS OFFERED
             12.1.14 MERCK KGAA
                        TABLE 164 MERCK KGAA: COMPANY OVERVIEW
                        FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT (2023)
                        TABLE 165 MERCK KGAA: PRODUCTS OFFERED
                        TABLE 166 MERCK KGAA: DEALS
             12.1.15 VERUM ANALYTICS, LLC
                        TABLE 167 VERUM ANALYTICS, LLC: COMPANY OVERVIEW
                        TABLE 168 VERUM ANALYTICS, LLC: PRODUCTS OFFERED
     12.2 OTHER PLAYERS 
             12.2.1 HAMILTON COMPANY
             12.2.2 ENDRESS+HAUSER GROUP SERVICES AG
             12.2.3 VIAVI SOLUTIONS INC.
             12.2.4 METROHM AG
             12.2.5 CONTROL DEVELOPMENT, INC.
             12.2.6 NECI
             12.2.7 SCHMIDT + HAENSCH
             12.2.8 SENSUM D.O.O.
             12.2.9 AMETEK, INC.
             12.2.10 SENTRONIC GMBH
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 248)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

The study involved four major activities in estimating the current size of the biopharmaceutical process analytical technology market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial biopharmaceutical process analytical technology market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the biopharmaceutical process analytical technology market. The primary sources from the demand side include biopharmaceutical manufacturer companies, research organizations, academic institutes, and process analytical service providing companies, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Biopharmaceutical Process Analytical  Technology Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 1,000 million, Tier 2 = USD 500–1,000 million, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the global biopharmaceutical process analytical technology market's size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the PAT business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and marketing executives.

To calculate the global market value, segmental revenues were calculated based on the revenue mapping of major solution/service providers. This process involved the following steps:

  • A list of major players operating in the biopharmaceutical process analytical technology market at the regional/country level
  • Product mapping of various manufacturers for each type of process analytical technology product at the regional/country level
  • Mapping of annual revenue generated by listed major players from PAT products segments (or the nearest reported business unit/product category)
  • Revenue mapping of major players to cover at least ~60% of the global market share as of 2023
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global process analytical technology market

Biopharmaceutical Process Analytical  Technology Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the global biopharmaceutical process analytical technology market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the biopharmaceutical process analytical technology market was validated using both top-down and bottom-up approaches.

Market Definition

The biopharmaceutical process analytical technology (PAT) market encompasses the tools, techniques, and systems used to monitor, control, and optimize the manufacturing processes of biopharmaceuticals. It involves advanced analytical methods aimed at ensuring product quality, efficiency, and compliance in the production of biopharmaceutical drugs.

Key Stakeholders

  • Process analytical technology manufacturers, suppliers, and providers
  • Biopharmaceutical firms
  • Contract research and manufacturing organizations
  • Academic and private research institutions
  • Research and Development (R&D) Companies
  • Medical Research Laboratories
  • Academic institutions and private research institutions
  • Regulatory Agencies
  • Quality Control and Assurance
  • Contract Manufacturing Organizations (CMOs)
  • Environmental and Safety Regulatory Bodies
  • Public and Private Research Institutions
  • Third-party Testing Laboratories

Objectives of the Study

  • To define, describe, and forecast the biopharmaceutical process analytical technology market based on type, product type, mode, application, and region
  • To provide detailed information regarding the major factors influencing the growth potential of the global biopharmaceutical process analytical technology market (drivers, restraints, opportunities, challenges, and trends)
  • To analyze the micro markets with respect to individual growth trends, future prospects, and contributions to the global biopharmaceutical process analytical technology market
  • To analyze key growth opportunities in the global biopharmaceutical process analytical technology market for key stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the RoE), Asia Pacific (Japan, China, India, and the RoAPAC), Latin America (Brazil, Mexico, and RoLATAM), and the Middle East & Africa
  • To profile the key players in the global biopharmaceutical process analytical technology market and comprehensively analyze their market shares and core competencies
  • To track and analyze the competitive developments undertaken in the global biopharmaceutical process analytical technology market, such as product launches; agreements; expansions; and mergers & acquisitions.

Available Customizations

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present x-ray detectors market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Geographic Analysis

  • Further breakdown of the Rest of Europe x-ray detectors market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
  • Further breakdown of the Rest of Asia Pacific diagnostic imaging market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
AST 9019
Published ON
May, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Biopharmaceutical Process Analytical Technology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback